1. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated (AL) amyloidosis;Abraham;Blood,2002
2. VAD-based regimens as primary treatment for multiple myeloma;Alexanian;American Journal of Hematology,1990
3. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine;Bradwell;Clinical Chemistry,2001
4. Guidelines on the provision of facilities for the care of adult patients with haematological malignancies (including leukaemia, lymphoma and severe bone marrow failure);British Committee for Standards in Haematology. Clinical Haematology Task Force;Clinical and Laboratory Haematology,1995
5. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy;Camoriano;New England Journal of Medicine,1987